Sulphydryls, Ascorbate and Oxygen As Modifiers of the Toxicity and Metabolism of Misonidazole in Vitro

Overview

Journal Br J Cancer

Specialty Oncology

Date 1980 Jun 1

PMID 7426314

Citations 8

Authors

Y C Taylor

A M Rauth

Affiliations

Soon will be listed here.

Abstract

Equimolar concentrations of cysteamine and reduced glutathione protected against the cytotoxicity of 5 mM misonidazole (MISO), whereas 5mM ascorbate enhanced its toxicity to hypoxic CHO and HeLa cells in vitro. Protection (reappearance of a shoulder region) could also be seen when cysteamine was added at later incubation times. These changes in toxicity were accompanied by changes in drug metabolism, as evidenced by radiochromatograms of cell extracts obtained after treatment with 14C-labelled MISO. In contrast, radiochromatograms obtained from cells treated with toxic levels of MISO (75 mM) under aerobic conditions indicated no drug metabolism. Both toxicity and drug metabolism could be immediately halted by introducing O2 during hypoxic exposure to MISO. These observations are discussed in terms of a possible model for the metabolism-mediated toxicity of MISO and the roles which sulphydryls and O2 may play.

Citing Articles

Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Wardman P Br J Radiol. 2018; 92(1093):20170915.

PMID: 29303355 PMC: 6435051. DOI: 10.1259/bjr.20170915.

The experimental development of bioreductive drugs and their role in cancer therapy.

Workman P, Stratford I Cancer Metastasis Rev. 1993; 12(2):73-82.

PMID: 8375022 DOI: 10.1007/BF00689802.

Flurbiprofen, a non-steroid anti-inflammatory agent, protects cells against hypoxic cell radiosensitizers in vitro.

Millar B, Jinks S, Powles T Br J Cancer. 1981; 44(5):733-40.

PMID: 7317272 PMC: 2010854. DOI: 10.1038/bjc.1981.260.

In vitro metabolism of misonidazole.

Josephy P, Palcic B, SKARSGARD L Br J Cancer. 1981; 43(4):443-50.

PMID: 7236487 PMC: 2010618. DOI: 10.1038/bjc.1981.65.

Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air.

Smith E, Stratford I, Adams G Br J Cancer. 1982; 46(1):117-26.

PMID: 7104191 PMC: 2011057. DOI: 10.1038/bjc.1982.173.

References

Hall E . Hypoxic sensitizers: radiobiological studies at the cellular level. Radiology. 1975; 117(2):453-7. DOI: 10.1148/117.2.453. View

Zannoni V, Sato P . Interaction with drugs and environmental chemicals. Effects of ascorbic acid on microsomal drug metabolism. Ann N Y Acad Sci. 1975; 258:119-31. DOI: 10.1111/j.1749-6632.1975.tb29272.x. View

Varghese A, Gulyas S, Mohindra J . Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 1976; 36(10):3761-5. View

Moore B, Palcic B, SKARSGARD L . Radiosensitizing and toxic effects on the 2-nitroimidazole Ro-07-0582 in hypoxic mammation cells. Radiat Res. 1976; 67(3):459-73. View

Urtasun R, Band P, Chapman J, Rabin H, Wilson A, Fryer C . Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative. Radiology. 1977; 122(3):801-4. DOI: 10.1148/122.3.801. View

Stratford I, Adams G . Effect of hyperthermia on differential cytotoxicity of a hypoxic cell radiosensitizer, Ro-07-0582, on mammalian cells in vitro. Br J Cancer. 1977; 35(3):307-13. PMC: 2025287. DOI: 10.1038/bjc.1977.44. View

Hall E, Astor M, Geard C, Biaglow J . Cytotoxicity of Ro-07-0582; enhancement by hyperthermia and protection by cysteamine. Br J Cancer. 1977; 35(6):809-15. PMC: 2025538. DOI: 10.1038/bjc.1977.122. View

Hall E, Biaglow J . Ro-07-0582 as a radiosensitizer and cytotoxic agent. Int J Radiat Oncol Biol Phys. 1977; 2(5-6):521-30. DOI: 10.1016/0360-3016(77)90163-8. View

Josephy P, Palcic B, SKARSGARD L . Ascorbate-enhanced cytotoxicity of misonidazole. Nature. 1978; 271(5643):370-2. DOI: 10.1038/271370a0. View

10.

Dische S . Hypoxic cell sensitisers in radiotherapy. Int J Radiat Oncol Biol Phys. 1978; 4(1-2):157-60. DOI: 10.1016/0360-3016(78)90132-3. View

11.

Stratford I, Gray P . Some factors affecting the specific toxicity of misonidazole towards hypoxic mammalian cells. Br J Cancer Suppl. 1978; 3:129-31. PMC: 2149360. View

12.

Bahnemann D, Basaga H, Dunlop J, Searle A, Willson R . Metronidazole (Flagyl), misonidazole (Ro 07-0582), iron, zinc and sulphur compounds in cancer therapy. Br J Cancer Suppl. 1978; 3:16-9. PMC: 2149407. View

13.

Palcic B, SKARSGARD L . Cytotoxicity of misonidazole and DNA damage in hypoxic mammalian cells. Br J Cancer Suppl. 1978; 3:54-9. PMC: 2149402. View

14.

Taylor Y, Rauth A . Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res. 1978; 38(9):2745-52. View

15.

Stratford I . Split dose cytotoxic experiments with misonidazole. Br J Cancer. 1978; 38(1):130-6. PMC: 2009678. DOI: 10.1038/bjc.1978.172. View

16.

Wong T, Whitmore G, Gulyas S . Studies on the toxicity and radiosensitizing ability of misonidazole under conditions of prolonged incubation. Radiat Res. 1978; 75(3):541-55. View

17.

Koch C, Howell R, Biaglow J . Ascorbate anion potentiates cytotoxicity of nitro-aromatic compounds under hypoxic and anoxic conditions. Br J Cancer. 1979; 39(3):321-9. PMC: 2009878. DOI: 10.1038/bjc.1979.56. View

18.

Wasserman T, Phillips T, Johnson R, Gomer C, Lawrence G, Sadee W . Initial United States clinical and pharmacologic evaluation of misonidazole (Ro-07-0582), an hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1979; 5(6):775-86. DOI: 10.1016/0360-3016(79)90061-0. View

19.

Knight R, Rowley D, Skolimowski I, Edwards D . Mechanism of action of nitroimidazole antimicrobial and antitumour radiosensitizing drugs. Effects of reduced misonidazole on DNA. Int J Radiat Biol Relat Stud Phys Chem Med. 1979; 36(4):367-77. DOI: 10.1080/09553007914551151. View

20.

Varghese A, Whitmore G . Binding of nitroreduction products of misonidazole to nucleic acids and protein. Cancer Clin Trials. 1980; 3(1):43-6. View